Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(2)
•••
Post by SizzlinSteakson Dec 27, 2017 1:55pm
100 Views
Post# 27232114

30.5

30.5Starting to move in the right direction again.

Level ll Quote for KALYTERA THERAPEUTICS INC (KALY: TSX Venture)
Bid Ask
Price Total Size # of Orders Price Total Size # of Orders
$0.30 500 1 $0.305 47500 7
$0.295 22000 3 $0.31 118500 8
$0.29 50000 3 $0.315 63500 4
$0.285 113000 3 $0.32 49000 11
$0.28 374500 6 $0.325 61500 7
$0.275 89500 8 $0.33 132000 9
$0.27 154000 18 $0.34 172000 5
$0.265 210500 22 $0.35 87500 11
$0.26 292000 20 $0.355 15000 1
$0.255 36000 4 $0.36 10000 2

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities